Therapie der clozapin-induzierten hypersalivation mit botulinum-toxin B

K. G. Kahl; P. Trillenberg; A. Kordon; R. Lencer; C. Klein; J. Hagenah

doi:10.1007/s00115-004-1800-x

Therapie der clozapin-induzierten hypersalivation mit botulinum-toxin B

Translated title of the contribution: Pharmacological strategies for clozapine-induced hypersalivation: Treatment with botulinum toxin B in one patient and review of the literature

K. G. Kahl^*, P. Trillenberg, A. Kordon, R. Lencer, C. Klein, J. Hagenah

^*Corresponding author for this work

8 Citations (Scopus)

Abstract

Hypersalivation is frequently observed in patients treated with clozapine. Current strategies to counteract sialorrhea include the introduction of antimuscarinergic (anticholinergic) and α ₂-agonistic treatment. However, the use of these substances is limited in part by lack of efficacy and by adverse side effects. In cases of intractable sialorrhea, the application of botulinum toxin may be a new and safe therapeutic option. We here present an overview on current treatment strategies for sialorrhea and describe a patient who received botulinum toxin B for clozapine-induced hypersalivation.

Translated title of the contribution	Pharmacological strategies for clozapine-induced hypersalivation: Treatment with botulinum toxin B in one patient and review of the literature
Original language	German
Journal	Nervenarzt
Volume	76
Issue number	2
Pages (from-to)	205-208
Number of pages	4
ISSN	0028-2804
DOIs	https://doi.org/10.1007/s00115-004-1800-x
Publication status	Published - 01.02.2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being
SDG 10 Reduced Inequalities

Access to Document

10.1007/s00115-004-1800-x

Cite this

@article{806ca06893bd49deb51404fe05c117d2,

title = "Therapie der clozapin-induzierten hypersalivation mit botulinum-toxin B",

abstract = "Hypersalivation is frequently observed in patients treated with clozapine. Current strategies to counteract sialorrhea include the introduction of antimuscarinergic (anticholinergic) and α 2-agonistic treatment. However, the use of these substances is limited in part by lack of efficacy and by adverse side effects. In cases of intractable sialorrhea, the application of botulinum toxin may be a new and safe therapeutic option. We here present an overview on current treatment strategies for sialorrhea and describe a patient who received botulinum toxin B for clozapine-induced hypersalivation.",

author = "Kahl, \{K. G.\} and P. Trillenberg and A. Kordon and R. Lencer and C. Klein and J. Hagenah",

year = "2005",

month = feb,

day = "1",

doi = "10.1007/s00115-004-1800-x",

language = "Deutsch",

volume = "76",

pages = "205--208",

journal = "Nervenarzt",

issn = "0028-2804",

publisher = "Springer Medizin",

number = "2",

}

TY - JOUR

T1 - Therapie der clozapin-induzierten hypersalivation mit botulinum-toxin B

AU - Kahl, K. G.

AU - Trillenberg, P.

AU - Kordon, A.

AU - Lencer, R.

AU - Klein, C.

AU - Hagenah, J.

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Hypersalivation is frequently observed in patients treated with clozapine. Current strategies to counteract sialorrhea include the introduction of antimuscarinergic (anticholinergic) and α 2-agonistic treatment. However, the use of these substances is limited in part by lack of efficacy and by adverse side effects. In cases of intractable sialorrhea, the application of botulinum toxin may be a new and safe therapeutic option. We here present an overview on current treatment strategies for sialorrhea and describe a patient who received botulinum toxin B for clozapine-induced hypersalivation.

AB - Hypersalivation is frequently observed in patients treated with clozapine. Current strategies to counteract sialorrhea include the introduction of antimuscarinergic (anticholinergic) and α 2-agonistic treatment. However, the use of these substances is limited in part by lack of efficacy and by adverse side effects. In cases of intractable sialorrhea, the application of botulinum toxin may be a new and safe therapeutic option. We here present an overview on current treatment strategies for sialorrhea and describe a patient who received botulinum toxin B for clozapine-induced hypersalivation.

UR - https://www.scopus.com/pages/publications/14544308876

U2 - 10.1007/s00115-004-1800-x

DO - 10.1007/s00115-004-1800-x

M3 - Zeitschriftenaufsätze

C2 - 15448913

AN - SCOPUS:14544308876

SN - 0028-2804

VL - 76

SP - 205

EP - 208

JO - Nervenarzt

JF - Nervenarzt

IS - 2

ER -

Therapie der clozapin-induzierten hypersalivation mit botulinum-toxin B

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this